The present invention relates to a combination of a 5-HT4 receptor agonist and a phosphodiesterase 4 (PDE4) inhibitor, and methods and uses therefore in the prevention and/or treatment of one or more disorders in which an increased acetylcholine release is desired; in particular in the prevention and/or treatment of gastrointestinal disorders, urinary disorders, and/or respiratory disorders.